Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,123 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,540 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 304) | recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 9 | Sep 23, 2026 | clinicaltrials |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | recruiting | Phase 1 / Phase 2 | 198 | Bristol-Myers SquibbINDUSTRY |
| 14 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT04291651 | UCSF PANC Cyst Registry(UCSF PCR) | recruiting | — | 4,000 | University of California, San FranciscoOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,130 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07146646 | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer | recruiting | Phase 2 | 27 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors(FiREBOLT) | recruiting | Phase 1 | 241 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | recruiting | Phase 3 | 614 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07522476 | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 30 | Virogin Biotech Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07728019 | Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM | recruiting | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835087 | Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer | recruiting | N/A | 36 | Beijing Friendship HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06271291 | Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts | recruiting | — | 30,000 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06329869 | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma(SG-ESCC) | recruiting | Phase 2 | 35 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06375915 | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy(PM-CARE) | recruiting | Phase 2 | 33 | Francesco De CobelliOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06929845 | Organoid Models of Hepatocellular Carcinoma | recruiting | N/A | 150 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07200141 | Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer(SIB-NCRT) | recruiting | Phase 2 | 156 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07639138 | Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | recruiting | Phase 2 | 32 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | recruiting | Phase 1 | 15 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07793695 | Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma(ZINC-1LT/IOHCC) | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06954116 | Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence(CCGLC-017) | recruiting | Phase 2 | 26 | Tongji HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07450859 | A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 2 | 39 | BicycleTx LimitedINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | recruiting | Early Phase 1 | 30 | University of ArizonaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02851784 | Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma | recruiting | Phase 2 / Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06275737 | POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric(POP-UP) | recruiting | N/A | 72 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06780111 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 298 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.(DARTS) | recruiting | Phase 3 | 30 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | recruiting | Phase 1 | 574 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07405151 | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 17, 2026 | clinicaltrials |
| NCT07824583 | A Study Evaluating a New Radiation Treatment Workflow (NGDS)(SPEED) | recruiting | N/A | 20 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05081024 | Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer | recruiting | — | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06252545 | Promoting CT Engagement for Pancreatic Cancer With App(PROCLAIM) | recruiting | N/A | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | recruiting | Phase 1 / Phase 2 | 768 | Boehringer IngelheimINDUSTRY | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06427941 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 630 | BeOne MedicinesINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT06574620 | Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment(ACCELERATE) | recruiting | N/A | 200 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07751341 | A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 84 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum | recruiting | Phase 2 | 140 | Vividion Therapeutics, Inc.INDUSTRY | 22 | Sep 16, 2026 | clinicaltrials |
| NCT04165772 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | recruiting | Phase 2 | 212 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06007846 | A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | recruiting | Phase 2 / Phase 3 | 12 | Inova Health Care ServicesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials